Last reviewed · How we verify
Cellvax Therapeutics Inc — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AstraZeneca · 1 shared drug class
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
- EMD Serono · 1 shared drug class
- EMS · 1 shared drug class
- Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 shared drug class
- Fujian Cancer Hospital · 1 shared drug class
- Anhui Shi, MD · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cellvax Therapeutics Inc:
- Cellvax Therapeutics Inc pipeline updates — RSS
- Cellvax Therapeutics Inc pipeline updates — Atom
- Cellvax Therapeutics Inc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cellvax Therapeutics Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cellvax-therapeutics-inc. Accessed 2026-05-16.